Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Gains from Investment Securities for 6 consecutive years, with $688000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to $688000.0, compared with a TTM value of $1.2 million through Sep 2025, up 4019.35%, and an annual FY2024 reading of $866000.0, up 1474.55% over the prior year.
  • Gains from Investment Securities was $688000.0 for Q3 2025 at Barinthus Biotherapeutics, up from -$340000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.6 million in Q1 2022 and bottomed at -$2.1 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $122370.1, with a median of $35500.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 14744.75% in 2022, while the deepest fall reached 102700.0% in 2022.
  • Year by year, Gains from Investment Securities stood at $2000.0 in 2021, then plummeted by 102700.0% to -$2.1 million in 2022, then skyrocketed by 98.49% to -$31000.0 in 2023, then soared by 2893.55% to $866000.0 in 2024, then dropped by 20.55% to $688000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for BRNS at $688000.0 in Q3 2025, -$340000.0 in Q2 2025, and $1000.0 in Q1 2025.